Skip to main content
Skip to main content
UTMD logo

Utah Medical Products, Inc. (UTMD) Stock Analysis

Educational signal · not a buy or sell recommendation · How to read this

$69.64 -$0.08 (-0.11%) |Exceptional · 86
Utah Medical Products, Inc. (UTMD) bottom line: Bullish Lean — our Council read (70/100) and AI Score (86/100) broadly agree. Strongest signal: Izzy Englander bullish · Biggest watch-out: Ken Griffin bearish.Educational signal, not a buy or sell recommendation. Compare sector peers → · Read the method →
MCap: $222M| P/E Ratio: 21.23| Vol: 31K| 52-wk range: $53.66 – $75.75

P/E 21.23 means the share price is 21.23 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $222M is the value of all shares combined. Beta 0.36: the stock has moved about 64% less than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jul 23, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Utah Medical Products, Inc. (UTMD) trades at $69.64 with MoonshotScore 86/100 (Grade A+). Market cap: $222M, Sector: Healthcare.

Price as of Sep 11, 2026 · Last analyzed: Jul 23, 2026
Utah Medical Products, Inc. develops, manufactures, and distributes specialized medical devices for labor and delivery, neonatal intensive care, women's health, and selected hospital procedures. The company reported a $222M market capitalization, 28.9% profit margin, 53.6% gross margin, 21.23 P/E ratio, 0.36 beta, and 1.93% dividend yield.

Analyst Coverage for UTMD: UTMD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates UTMD against Healthcare peers across nine fundamental dimensions and assigns a relatively strong fundamental profile based on the underlying data.

Watch the UTMD film Every key number, told as a short cinematic story — just press play. ~2 min

These figures come from statements filed 12 months ago — the most recent this company has published.

Council Score · Weighted Average of 3 Disciplines
Bullish Lean 70/100 · A

UTMD: 2/3 scored disciplines lean bullish. Dominant signal: Izzy Englander bullish.

How is this calculated? →
MoonshotScore · Five-pillar engine · 86/100
Business Quality
Strong Is this a genuinely good business?
Financial Safety
Strong Could this blow up on me?
Valuation
Moderate Am I paying a fair price?
Growth Durability
Weak Is the growth real and likely to last?
Momentum
Moderate Is the market already moving on this?

Strongest side: Financial Safety (10/10, Strong). Weakest side: Growth Durability (4/10, Weak).

Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated)Ray Dalio
Favorable read
Griffin-style lens (simulated)Ken Griffin
Unfavorable read
Simons-style lens (simulated)Jim Simons
Favorable read
Englander-style lens (simulated)Izzy Englander
Favorable read
Klarman-style lens (simulated)Seth Klarman
Favorable read
Moon AI lens (model)
Favorable read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Neutral
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

Why this analysis is different

  • A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
  • An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
  • Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Utah Medical Products, Inc. (UTMD) Healthcare & Pipeline Overview

CEOKevin L. Cornwell
Employees146
HeadquartersMidvale, UT, US
IPO Year1999

Utah Medical Products is a specialized healthcare-device manufacturer serving labor and delivery, neonatal intensive care, women’s health, and selected hospital procedures. Its portfolio combines disposable catheters, monitoring accessories, electrosurgical systems, gynecological instruments, and procedure kits, supported by direct service, sales teams, consultants, and manufacturer representatives.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Jul 23, 2026

What Is the Investment Thesis for UTMD?

AI-written as of Jul 23, 2026 — figures and tone reflect the data available then, not today's score.

UTMD's research profile is defined by specialized medical-device manufacturing, a broad portfolio of disposable and capital-linked procedure products, and exposure to recurring clinical workflows in labor and delivery, neonatal intensive care, and women's health. Reported gross margin is 53.6%, profit margin is 28.9%, and P/E is 21.23, providing measurable indicators of profitability and valuation. Market capitalization is $222M, while beta of 0.36 indicates relatively low reported share-price sensitivity compared with a beta of 1, although no benchmark or observation period is provided. Potential value drivers include cross-selling across hospital departments, continued use of established product families, and distribution through multiple channels, including direct sales, consultants, and manufacturer representatives. The portfolio spans monitoring accessories, catheters, procedure trays, electrosurgical systems, gynecological instruments, urinary-care devices, and neonatal products, which may provide multiple product-level revenue sources. Key analytical risks include the company's concentration in specialized clinical categories, unknown regulatory and reimbursement conditions, and the absence of quantified product-level or geographic performance data. These facts are presented for independent research rather than as a recommendation.

Based on FMP financials and quantitative analysis

UTMD Key Highlights

AI-written as of Jul 23, 2026 — figures and tone reflect the data available then, not today's score.

Market capitalization of $222M, indicating a small-cap medical-device company based on the provided fundamentals.

  • Gross margin of 53.6%, reflecting the reported difference between sales and cost of goods sold.
  • Profit margin of 28.9%, indicating reported net profitability.
  • P/E ratio of 21.23, providing a reported earnings-based valuation metric without a supplied historical or peer comparison.
  • Beta of 0.36 and dividend yield of 1.93%, representing the supplied share-volatility and dividend metrics.

Who Are UTMD's Competitors?

UTMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
OSUR OraSure Technologies, Inc. $3.23 -3.87% $222M 315-pillar
INFU InfuSystem Holdings, Inc. $12.07 -0.41% $244M 865-pillar
PDEX Pro-Dex, Inc. $59.84 -1.42% $191M 815-pillar
NNNN Anbio Biotechnology $6.29 -3.30% $276M 575-pillar
SMTI Sanara MedTech Inc. $35.03 0.00% $322M 355-pillar
KRMD KORU Medical Systems, Inc. $3.15 0.00% $145M 385-pillar
ANGO AngioDynamics, Inc. $15.34 +0.66% $634M 385-pillar
MBOT Microbot Medical Inc. $1.49 +1.71% $67.7M

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are UTMD's Key Strengths?

Diversified portfolio of medical devices serving labor and delivery, neonatal intensive care, women's health, and other hospital procedures.

  • Reported gross margin of 53.6% and profit margin of 28.9%.
  • Established since 1978 with 155 employees and headquarters in Midvale, Utah.
  • Multiple distribution routes and products spanning disposable, procedural, monitoring, electrosurgical, and specialty categories.

What Are UTMD's Weaknesses?

Small reported market capitalization of $222M relative to larger medical-device companies.

  • Substantial portfolio exposure to specialized maternity-care and women's-health categories.

What Could Drive UTMD Stock Higher?

UTMD catalyst: Continued supply of labor-and-delivery and neonatal intensive-care products through UTMD's established customer and distribution channels.

  • Product breadth in women's health, including electrosurgical systems, laparoscopic instruments, uterine-assessment devices, contraception products, and urinary-care systems.
  • Cross-selling potential across hospitals, outpatient clinics, physicians' offices, labor-and-delivery wards, neonatal intensive care units, and women's-health centers.
  • Continued demand for disposable catheters, filters, pressure transducers, dialysis sets, feeding devices, urinary drainage systems, and procedure trays.

What Are the Key Risks for UTMD?

Regulatory approval, compliance, or product-quality requirements affecting medical devices.

  • Competitive pressure from other suppliers of labor-and-delivery, neonatal, women's-health, gynecological, urinary-care, and hospital-procedure products.
  • Customer concentration or purchasing pressure among hospitals, clinics, and physicians' offices.
  • Substantial portfolio exposure to women's health and gynecological interventions, with category-level revenue dependence not provided.
  • Limited disclosed financial and operating detail in the supplied data, including Unknown revenue, earnings, cash flow, debt, geographic mix, research-and-development spending, and market share.

What Are the Growth Opportunities for UTMD?

  • Ongoing: Expansion across labor-and-delivery workflows is a potential product-level growth avenue because UTMD already supplies fetal monitoring accessories, vacuum-assisted delivery systems, and other childbirth tools. The company can also serve adjacent maternity-care needs through its neonatal and women's-health portfolios. The relevant differentiator is the existing concentration of products around childbirth-related clinical settings.
  • Ongoing: Neonatal intensive care provides an established clinical area for UTMD's DISPOSA-HOOD, GESCO, PALA-NATE, and MYELO-NATE products. A broader neonatal portfolio could support additional hospital relationships or increased use across procedures, but no pipeline, approval schedule, unit volume, or neonatal-care market estimate is provided. The available evidence supports only that UTMD already serves neonatal intensive care units and offers multiple specialized devices designed for newborn respiratory, vascular, oral-protection, and lumbar-sampling applications.
  • Ongoing: Women's health and gynecological interventions represent a substantial portion of UTMD's product range. LETZ, FINESSE+, specialized electrodes, FILTRESSE, Femcare laparoscopic instruments, Filshie Clip, PATHFINDER PLUS, LIBERTY, ENDOCURETTE, TVUS/HSG-Cath, and LUMIN give the company multiple products across electrosurgery, laparoscopy, contraception, urinary care, uterine assessment, and uterine manipulation. Product breadth is the identifiable strategic asset in this area.
  • Ongoing: Cross-selling through UTMD's mixed distribution model could support growth across hospitals, outpatient clinics, physicians' offices, and specialized departments. The company uses direct customer service and sales teams, independent consultants, and manufacturer representatives, creating several routes to reach healthcare customers. The identifiable opportunity is to place multiple product categories with organizations that require labor, neonatal, women's-health, and procedural supplies.
  • Ongoing: Development or broader utilization of disposable and procedure-oriented products could create recurring demand within existing clinical workflows. UTMD supplies disposable pressure transducers, filters, catheters, dialysis sets, urinary drainage systems, feeding devices, procedure trays, and electrosurgical accessories in addition to reusable or equipment-linked products. The identifiable opportunity is the breadth of disposable products across several healthcare settings.

What Are UTMD's Competitive Advantages?

  • Specialized product knowledge across labor and delivery, neonatal intensive care, and women's health.
  • Broad portfolio spanning disposable supplies, monitoring accessories, electrosurgical systems, procedure trays, and specialty instruments.
  • Established company history dating to 1978, according to the provided data.
  • Multiple distribution channels, including direct sales and service, independent consultants, and manufacturer representatives.
  • Product coverage across several clinical departments and healthcare settings, enabling potential portfolio breadth within institutional customers.

What Does UTMD Do?

Utah Medical Products, Inc. is a healthcare technology company focused on creating, producing, and supplying medical devices for the healthcare sector. Established in 1978, the company is headquartered in Midvale, Utah, and has 155 employees. Its product portfolio is concentrated in clinical areas that include labor and delivery, neonatal intensive care, women's health, gynecological interventions, urinary care, dialysis, feeding, blood-pressure monitoring, and catheterization procedures. UTMD's labor-and-delivery portfolio includes fetal monitoring accessories, vacuum-assisted delivery systems, and other specialized tools used in childbirth. In neonatal care, the company supplies DISPOSA-HOOD infant respiratory hoods, GESCO umbilical vessel catheters, PALA-NATE silicone oral protection devices, and MYELO-NATE lumbar sampling kits. It also offers products used in broader hospital settings, including DELTRAN PLUS blood-pressure monitoring systems, disposable peritoneal dialysis sets under the DIALY-NATE name, URI-CATH urinary drainage systems, NUTRI-CATH and NUTRI-LOK feeding devices, HEMO-NATE disposable filters, catheterization procedure trays, disposable pressure transducers, related accessories, and molded parts. A substantial portion of the portfolio addresses women's health and gynecological procedures. Products include the LETZ system for excising cervical intraepithelial neoplasia and other lower-genital-tract lesions, FINESSE+ generators, loop, ball, and needle electrodes, FILTRESSE evacuators, Femcare trocars and cannulae, EPITOME and OptiMicro electrosurgical devices, Filshie Clip female surgical contraception devices, PATHFINDER PLUS endoscopic irrigation devices, suprapubic catheterization products, LIBERTY urinary-incontinence treatment and control systems, ENDOCURETTE uterine endometrial sampling devices, TVUS/HSG-Cath products for assessing uterine abnormalities and bleeding, and the LUMIN uterine manipulator for laparoscopic procedures. UTMD serves neonatal intensive care units, labor-and-delivery wards, women's health centers within hospitals, outpatient clinics, and physicians' offices. Distribution combines direct customer service and sales teams with independent consultants and manufacturer representatives. The company's stated market position is therefore best characterized as a specialized medical-device supplier with a diversified product range concentrated in maternity care, neonatal care, and women's health.

What Products and Services Does UTMD Offer?

  • Manufactures fetal monitoring accessories and vacuum-assisted delivery systems for labor and delivery departments.
  • Supplies neonatal devices including respiratory hoods, umbilical vessel catheters, oral protection devices, and lumbar sampling kits.
  • Produces blood-pressure monitoring systems, disposable pressure transducers, dialysis sets, urinary drainage systems, feeding devices, and filters.
  • Provides catheterization procedure trays and related accessories and molded parts for healthcare procedures.
  • Offers women's-health and gynecological products including electrosurgical systems, electrodes, evacuators, trocars, cannulae, and laparoscopic instruments.
  • Supplies contraception, endoscopic irrigation, suprapubic catheterization, urinary-incontinence, uterine-sampling, uterine-assessment, and uterine-manipulation products.
  • Distributes products through direct customer service and sales teams, independent consultants, and manufacturer representatives.

How Does UTMD Make Money?

  • Generates revenue by creating, manufacturing, and supplying medical devices and related accessories to healthcare customers.
  • Sells disposable products such as filters, catheters, pressure transducers, dialysis sets, feeding devices, and procedure supplies.
  • Provides equipment-linked and procedural products, including electrosurgical generators, electrodes, monitoring systems, laparoscopic instruments, and gynecological tools.
  • Reaches customers through direct service and sales teams, independent consultants, and manufacturer representatives.
  • Serves hospitals, neonatal intensive care units, labor-and-delivery wards, outpatient clinics, women's-health centers, and physicians' offices.

What Industry Does UTMD Operate In?

UTMD operates in the healthcare sector's medical-instruments-and-supplies industry, with a specialized focus on labor and delivery, neonatal intensive care, women's health, gynecological procedures, urinary care, dialysis, feeding, and hospital catheterization. Its competitive landscape includes medical-device manufacturers and suppliers serving overlapping procedural categories. The company's positioning is supported by product breadth across disposable devices, electrosurgical equipment, procedure trays, monitoring accessories, and specialty instruments.

Who Are UTMD's Key Customers?

  • Labor-and-delivery departments and hospital maternity wards.
  • Neonatal intensive care units and healthcare providers treating newborns.
  • Women's-health centers, gynecological departments, outpatient clinics, and physicians' offices.
  • Hospitals and clinical facilities requiring monitoring, catheterization, dialysis, urinary-care, feeding, and procedural devices.
  • Healthcare providers performing laparoscopic, electrosurgical, uterine-assessment, contraception, or urinary-incontinence procedures.
Model self-rating on this text: 52% (not a measure of the evidence) Updated: Jul 23, 2026

Research confidence

High 85/100

Broad, current evidence sits behind this analysis.

  • Scored on 100% of our measures
  • Price is current
  • Latest filing 30 days ago
  • No analyst coverage

Why 86?

Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.

What is helping

  • +0.60 Bankruptcy-risk score (Financial Strength)
  • +0.60 Short-term liquidity (Financial Strength)
  • +0.54 Financial-health checklist (Financial Strength)

What is holding it back

  • -0.41 5-year net income per share (Growth)
  • -0.07 Earnings growth (Growth)
  • -0.07 Operating income growth (Growth)

Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →

MoonshotScore History

Recorded daily since 2026-08-23 · 19 snapshots

2026-08-23 86
2026-08-26 86
2026-08-29 87
2026-09-01 85
2026-09-04 85
2026-09-07 85
2026-09-10 85

What changed?

The grade moved from 86 to 85 (-1).

What moved it up or down:

  • -12 Valuation
  • -5 Growth Durability

Held back by:

  • +3 Momentum

Over the same 18 days the stock moved -3.2%.

Company Profile

Utah Medical Products, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Midvale, US. The company is led by CEO Kevin L. Cornwell. UTMD has traded publicly since 1999.

ROE 9%

Key Financial Metrics

Return on equity for Utah Medical Products, Inc. stands at 8.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.4%, showing how much profit it generates from its asset base. UTMD trades at a trailing price-to-earnings ratio of 21.23, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 48.62 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.7%, the inverse of the P/E and a quick read on earnings relative to price.

UTMD Valuation & Market Position

With a $222M market cap, Utah Medical Products, Inc. sits in the micro-cap segment of the market. Relative to its peer group, UTMD's quantitative score of 86/100 is above the peer average of 52/100.

Quarterly Financial Performance: Utah Medical Products, Inc.

Revenue for Utah Medical Products, Inc. came in at $8.5M during Q2 FY2026, a 2.2% contraction versus the preceding quarter. The company recorded net income of $2.7M, with diluted EPS of $0.84. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, UTMD averaged $0.82 in diluted EPS.

F-Score 7/9

Financial Health

Utah Medical Products, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 55.65 places it in the safe zone, indicating low near-term bankruptcy risk.

Net selling

Insider Activity

Over the past six months, Utah Medical Products, Inc. insiders filed 2 SEC Form 4 transactions — 2 sales and 0 purchases. On net that is roughly 200 shares disposed (about $14K), a signal worth weighing alongside the fundamentals.

UTMD Financials

Fundamental Snapshot

Revenue Growth (FY)
-5.8%
Net Income Growth (FY)
-18.7%
EPS Growth (FY)
-12.1%
Free Cash Flow Growth (FY)
-1.9%
P/E (TTM)
21.23
Return on Equity (TTM)
+8.7%
Current Ratio
48.6
EV/EBITDA (TTM)
15.2

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Diversified portfolio of medical devices serving labor and delivery, neonatal intensive care, women's health, and other hospital procedures.
  • Reported gross margin of 53.6% and profit margin of 28.9%.
  • Established since 1978 with 155 employees and headquarters in Midvale, Utah.
  • Multiple distribution routes and products spanning disposable, procedural, monitoring, electrosurgical, and specialty categories.

Bear Case

  • Small reported market capitalization of $222M relative to larger medical-device companies.
  • Substantial portfolio exposure to specialized maternity-care and women's-health categories.
  • Potential: Regulatory approval, compliance, or product-quality requirements affecting medical devices.
  • Potential: Competitive pressure from other suppliers of labor-and-delivery, neonatal, women's-health, gynecological, urinary-care, and hospital-procedure products.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · September 2026

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q2 FY2026 $9M $3M $0.84
Q1 FY2026 $9M $3M $0.82
Q4 FY2025 $9M $3M $0.80
Q3 FY2025 $10M $3M $0.82

Q2 FY2026 · filed 12 Aug 2026 · SEC EDGAR →

Based on FMP financials and quantitative analysis

UTMD Latest News

UTMD Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for UTMD.

Price Targets

Wall Street price target analysis for UTMD.

UTMD MoonshotScore

86/100

What does this score mean?

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. UTMD scores 86/100 (Grade A+): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Leadership: Kevin L. Cornwell

CEO title: Unknown; provided as managing 155 employees

Kevin L. Cornwell is the leadership executive managing Utah Medical Products, Inc.'s 155 employees. No information is provided regarding his tenure as chief executive, operational responsibilities beyond managing the employee base, or leadership experience in medical devices, healthcare technology, manufacturing, or regulatory affairs.

Track Record: His quantified management scope in the source is the company's 155 employees.

UTMD Healthcare Stock FAQ

What does the AI Score mean for UTMD?

UTMD holds an AI Score of 86/100 (Grade: A+). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is UTMD a good stock?

Stock Expert AI does not rate UTMD buy, sell or hold. Utah Medical Products, Inc. carries a MoonshotScore of 86/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.

How does UTMD navigate medical-device regulation and compliance?

Utah Medical Products, Inc. operates in medical instruments and supplies, an industry in which products generally require compliance with applicable healthcare and medical-device requirements.

What are the key factors to evaluate for UTMD?

Utah Medical Products, Inc. (UTMD) holds a MoonshotScore of 86/100 (high). P/E: 21.23x vs the S&P 500's ~20-25x. Not financial advice.

How frequently does UTMD data refresh on this page?

UTMD's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven UTMD's recent stock price performance?

Utah Medical Products, Inc. (UTMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified portfolio of medical devices serving labor and delivery, neonatal intensive care, women's health, and other hospital procedures. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider UTMD overvalued or undervalued right now?

Utah Medical Products, Inc. (UTMD) trades at 21.23x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of UTMD?

Yes, most major brokerages offer fractional shares of Utah Medical Products, Inc. (UTMD) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track UTMD's earnings and financial reports?

Utah Medical Products, Inc. (UTMD) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for UTMD earnings announcements.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated MoonshotScore as of
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • All company, product, leadership, and financial facts are limited to the supplied source data.
  • No investment recommendation is made.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

More Stocks We Cover